Jefferies analyst Brian Tanquilut maintained a Buy rating on Radnet (RDNT – Research Report) today and set a price target of $77.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Brian Tanquilut has given his Buy rating due to a combination of factors that highlight Radnet’s strong performance and growth potential. Despite challenges from wildfires in Southern California and severe winter weather on the East Coast and Texas, Radnet demonstrated resilience with a quick recovery in imaging volumes. This recovery contributed to a revenue and EBITDA beat in the first quarter, surpassing Street estimates.
The company’s strategic initiatives, such as de novo and joint venture strategies, continue to bolster utilization rates and financial performance. Additionally, Radnet’s substantial cash balance and potential mergers and acquisitions present significant growth opportunities. The anticipated rollout of AI technologies and operational cost savings further enhance the company’s outlook, making the stock an attractive investment opportunity.
Tanquilut covers the Healthcare sector, focusing on stocks such as Radnet, Acadia Healthcare, and Option Care Health. According to TipRanks, Tanquilut has an average return of 3.6% and a 51.69% success rate on recommended stocks.
In another report released today, Truist Financial also reiterated a Buy rating on the stock with a $74.00 price target.